Skip to main content

Ventavis Dosage

Medically reviewed by Last updated on Oct 11, 2021.

Generic name: iloprost 10ug in 1mL
Dosage form: inhalation solution

Recommended Dosing

VENTAVIS is intended to be inhaled using the I-neb® AAD® System. The recommended initial inhaled dose is 2.5 mcg (as delivered at the mouthpiece). If well tolerated, increase dosing to 5.0 mcg and maintain at that dose; otherwise maintain the dose at 2.5 mcg [see Warnings and Precautions (5.1)]. VENTAVIS should be taken 6 to 9 times per day (no more than once every 2 hours) during waking hours, according to individual need and tolerability. The maximum daily dose evaluated in clinical studies was 45 mcg (5 mcg 9 times per day).

Direct mixing of VENTAVIS with other medications in the I-neb® AAD® System has not been evaluated; do not mix with other medications. To avoid potential interruptions in drug delivery due to equipment malfunctions, the patient should have easy access to a back-up I-neb®AAD® System.

VENTAVIS is supplied in 1 mL ampules in two concentrations: 10 mcg/mL and 20 mcg/mL.

Delivered dose from ampule of :
Nebulizer 10 mcg/mL 20 mcg/mL
I-neb® AAD® 2.5 or 5 mcg from one ampule 5 mcg from one ampule

The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Transitioning patients to the 20 mcg/mL concentration using the I-neb® AAD® System will decrease treatment times to help maintain patient compliance.

For each inhalation session, the entire contents of each opened ampule of VENTAVIS should be transferred into the I-neb® AAD® System medication chamber immediately before use. Discard any solution remaining in the medication chamber after each inhalation session. Patients should follow the manufacturer's instructions for cleaning the I-neb® AAD® System components after each dose administration.

Use in Patients with Pre-existing Hepatic Impairment

Because iloprost elimination is reduced in patients with impaired liver function [see Use in Specific Populations (8.6)], consider increasing the dosing interval (e.g., 3–4 hours between doses depending on the patient's response at the end of the dose interval) in patients with Child-Pugh Class B or C hepatic impairment.

Use in Patients with Pre-existing Renal Impairment

Dose adjustment is not required in patients who are not on dialysis. The effect of dialysis on iloprost is unknown [see Use in Specific Populations (8.7)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.